First line treatment of VMA

Article

Ocriplasmin found to be a useful alternative

The vitreous of the eye is a clear, gellike structure with complex pathogenic mechanisms. Recent research is proving that abnormalities in vitreoretinal adhesion play an integral role in a variety of retinal diseases. Liquefaction and detachment of the vitreous from the retina is relatively common and does not cause problems. However, incomplete separation of the vitreous from the retina, vitreomacular adhesion (VMA), can cause tractional forces that distort vision and lead to other pathologies.

VMA is implicated in the pathophysiology of numerous visual disorders including macular holes, agerelated macular degeneration (AMD), retinal vein occlusions and diabetic macular oedema (DME). A study of diseases of the vitreomacular interface found that VMA existed in 16% of cases of macular hole and 52% of cases of epiretinal membrane. In exudative AMD, incidence of VMA can be as high as 38%. While the exact cause–effect relationship is not known, it seems clear that VMA is the initiator to a variety of ocular pathologies.

Advancements in high-resolution optical coherence tomography (OCT) allow physicians to verify the presence of VMA before deterioration of visual acuity is detectable. Thus the current treatment paradigm for VMA consists of 'watchful waiting' to see if the adhesion will resolve itself by evolving to complete posterior vitreous detachment. If notable visual symptoms occur, visual acuity can deteriorate rapidly and efficient intervention is required to halt progression.3

In a study of untreated eyes with DME, only 25% (n = 60) of eyes with VMA at study entry showed spontaneous vitreomacular separation, and the prevalence of improved visual acuity of more than two lines was significantly higher in eyes with vitreomacular separation at study entry (36%, n = 22) than in eyes without (15%, 9/60).4

When symptoms deteriorate, the accepted method of relieving adhesion and the resulting tractional forces is vitrectomy. While this has been shown to be successful, mechanical separation has also been known to leave vitreous fibrils on the internal limiting membrane, which may lead to cell proliferation and the forming of a scaffold that would generate further traction.8,9 Without those additional complications, vitrectomy remains a major surgical procedure with associated risks, and in some cases requires considerable face-down time for the patient.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.